|

INCYTE CORP (INCY)

US45337C1027 - Common Stock

54.7  -0.48 (-0.87%)

After market: 54.7 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

INCYTE CORP

NASDAQ:INCY (12/8/2023, 7:00:02 PM)

After market: 54.7 0 (0%)

54.7

-0.48 (-0.87%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap12.26B
Shares
PE17.76
Fwd PE11.91
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

INCY Daily chart

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,324 full-time employees. The firm also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. The company operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.

Company Info

INCYTE CORP

1801 Augustine Cut-Off

Wilmington DELAWARE 19803

P: 13024986700.0

CEO: Herve Hoppenot

Employees: 2324

Website: https://www.incyte.com/

INCY News

News Image4 days ago - ChartmillDespite its impressive fundamentals, NASDAQ:INCY remains undervalued.

Despite its impressive fundamentals, INCYTE CORP (NASDAQ:INCY) remains undervalued.

News Image12 days ago - ChartmillInvestors should take note of NASDAQ:INCY, a growth stock that remains attractively priced.

Investors should take note ofINCYTE CORP (NASDAQ:INCY), a growth stock that remains attractively priced.

News Image18 days ago - Seeking AlphaGoldman Sachs cuts Incyte to hold, cites Jakafi outlook uncertainty (INCY)

Goldman Sachs downgraded Incyte (INCY) due to uncertainty surrounding the lifecycle management of its drug Jakafi ahead of its loss of market exclusivity. Read more here.

News Imagea month ago - InvestorPlace3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024

Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year.

News Imagea month ago - Market News VideoOversold Conditions For Incyte (INCY)
News Imagea month ago - InvestorPlace7 Underappreciated Biotech Stocks to Pick Up on the Cheap

With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.

INCY Twits

Here you can normally see the latest stock twits on INCY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example